Dipti Chand, R. Gosavi, A. Chakraborty, Tejas Kungar, Yash Paliwal
{"title":"一个有趣的蛋白尿病例:AL淀粉样变","authors":"Dipti Chand, R. Gosavi, A. Chakraborty, Tejas Kungar, Yash Paliwal","doi":"10.25259/vjim_16_2021","DOIUrl":null,"url":null,"abstract":"Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognise because of its broad range of manifestations and what often are vague symptoms. The clinical syndromes at presentation include nephrotic-range proteinuria with or without renal dysfunction, hepatomegaly, congestive heart failure and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines approaches to diagnosis, assessment of disease severity and treatment of AL amyloidosis. We describe a case of a 54--year-old male patient with monoclonal gammopathy with AL amyloidosis.","PeriodicalId":232453,"journal":{"name":"Vidarbha Journal of Internal Medicine","volume":"6 3","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An Interesting Case of Proteinuria: AL Amyloidosis\",\"authors\":\"Dipti Chand, R. Gosavi, A. Chakraborty, Tejas Kungar, Yash Paliwal\",\"doi\":\"10.25259/vjim_16_2021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognise because of its broad range of manifestations and what often are vague symptoms. The clinical syndromes at presentation include nephrotic-range proteinuria with or without renal dysfunction, hepatomegaly, congestive heart failure and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines approaches to diagnosis, assessment of disease severity and treatment of AL amyloidosis. We describe a case of a 54--year-old male patient with monoclonal gammopathy with AL amyloidosis.\",\"PeriodicalId\":232453,\"journal\":{\"name\":\"Vidarbha Journal of Internal Medicine\",\"volume\":\"6 3\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vidarbha Journal of Internal Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.25259/vjim_16_2021\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vidarbha Journal of Internal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25259/vjim_16_2021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An Interesting Case of Proteinuria: AL Amyloidosis
Light-chain (AL) amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. The disease often is difficult to recognise because of its broad range of manifestations and what often are vague symptoms. The clinical syndromes at presentation include nephrotic-range proteinuria with or without renal dysfunction, hepatomegaly, congestive heart failure and autonomic or sensory neuropathy. Recent diagnostic and prognostic advances include the serum free light-chain assay, cardiac magnetic resonance imaging and serologic cardiac biomarkers. Treatment strategies that have evolved during the past decade are prolonging survival and preserving organ function in patients with this disease. This review outlines approaches to diagnosis, assessment of disease severity and treatment of AL amyloidosis. We describe a case of a 54--year-old male patient with monoclonal gammopathy with AL amyloidosis.